ATE165918T1 - Aus bestandteilen im gehirngewebe der säugetiere ableitbare dichte mikrokugeln und dagegen gerichtete antikörper - Google Patents
Aus bestandteilen im gehirngewebe der säugetiere ableitbare dichte mikrokugeln und dagegen gerichtete antikörperInfo
- Publication number
- ATE165918T1 ATE165918T1 AT95903728T AT95903728T ATE165918T1 AT E165918 T1 ATE165918 T1 AT E165918T1 AT 95903728 T AT95903728 T AT 95903728T AT 95903728 T AT95903728 T AT 95903728T AT E165918 T1 ATE165918 T1 AT E165918T1
- Authority
- AT
- Austria
- Prior art keywords
- dms
- antibodies
- mammals
- components
- cerebral amyloid
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 1
- 210000005013 brain tissue Anatomy 0.000 title 1
- 239000004005 microsphere Substances 0.000 title 1
- 230000002490 cerebral effect Effects 0.000 abstract 5
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 4
- 210000001124 body fluid Anatomy 0.000 abstract 3
- 230000007505 plaque formation Effects 0.000 abstract 3
- 210000004556 brain Anatomy 0.000 abstract 2
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/168,250 US5525339A (en) | 1986-08-27 | 1993-12-17 | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE165918T1 true ATE165918T1 (de) | 1998-05-15 |
Family
ID=22610731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95903728T ATE165918T1 (de) | 1993-12-17 | 1994-12-19 | Aus bestandteilen im gehirngewebe der säugetiere ableitbare dichte mikrokugeln und dagegen gerichtete antikörper |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US5525339A (de) |
| EP (1) | EP0733214B1 (de) |
| JP (1) | JPH09507748A (de) |
| AT (1) | ATE165918T1 (de) |
| AU (1) | AU702153B2 (de) |
| CA (1) | CA2175451C (de) |
| DE (1) | DE69410116T2 (de) |
| DK (1) | DK0733214T3 (de) |
| ES (1) | ES2118545T3 (de) |
| WO (1) | WO1995016917A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
| US5525339A (en) * | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
| US6413940B1 (en) * | 1997-02-07 | 2002-07-02 | Nymox Corporation | Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS |
| WO2003074558A2 (en) * | 2002-03-04 | 2003-09-12 | Nymox Corporation | Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom |
| US7514407B2 (en) * | 2002-03-04 | 2009-04-07 | Nymox Corporation | Spheron component peptides and pharmaceutical compositions |
| US20040146512A1 (en) * | 2002-10-09 | 2004-07-29 | Arnon Rosenthal | Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| UY29504A1 (es) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| EP1959996A2 (de) | 2005-12-12 | 2008-08-27 | AC Immune S.A. | Monoklonaler antikörper |
| EP2046833B9 (de) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanisierter antikörper gegen amyloid beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP2598882B1 (de) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose |
| EP3533803B1 (de) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antikörper |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816416A (en) * | 1986-08-27 | 1989-03-28 | Paul Averback | Microspheric bodies for use in screening therapies for Azheimer's disease and related conditions |
| US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
| US5525339A (en) * | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
| US4919915A (en) * | 1987-03-03 | 1990-04-24 | Paul Averback | Method for detecting the ability to prevent red-to-green congophilic birefringence |
| US6727278B1 (en) * | 1986-08-27 | 2004-04-27 | Dms Pharmaceutical Inc. | Pharmaceutically active agents that impede amyloid formation in vivo |
| US5262332A (en) * | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
| US5234814A (en) * | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
| US5100645A (en) * | 1990-10-19 | 1992-03-31 | Royal Institution For The Advancement Of Learning (Mcgill Univ.) | Method of diagnosis of amyloidosis |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US6413940B1 (en) * | 1997-02-07 | 2002-07-02 | Nymox Corporation | Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS |
| US6130221A (en) * | 1997-03-05 | 2000-10-10 | Nymox Corporation | Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions |
| US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
-
1993
- 1993-12-17 US US08/168,250 patent/US5525339A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 JP JP7516431A patent/JPH09507748A/ja active Pending
- 1994-12-19 AT AT95903728T patent/ATE165918T1/de not_active IP Right Cessation
- 1994-12-19 ES ES95903728T patent/ES2118545T3/es not_active Expired - Lifetime
- 1994-12-19 CA CA002175451A patent/CA2175451C/en not_active Expired - Fee Related
- 1994-12-19 DE DE69410116T patent/DE69410116T2/de not_active Expired - Fee Related
- 1994-12-19 WO PCT/CA1994/000689 patent/WO1995016917A1/en not_active Ceased
- 1994-12-19 DK DK95903728T patent/DK0733214T3/da active
- 1994-12-19 EP EP95903728A patent/EP0733214B1/de not_active Expired - Lifetime
- 1994-12-19 AU AU12695/95A patent/AU702153B2/en not_active Ceased
-
1996
- 1996-06-10 US US08/660,886 patent/US6309892B1/en not_active Expired - Fee Related
-
2001
- 2001-10-29 US US09/984,304 patent/US20020028473A1/en not_active Abandoned
-
2004
- 2004-12-29 US US11/024,223 patent/US20050191711A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050191711A1 (en) | 2005-09-01 |
| EP0733214A1 (de) | 1996-09-25 |
| AU702153B2 (en) | 1999-02-18 |
| DK0733214T3 (da) | 1999-03-15 |
| CA2175451C (en) | 2000-10-31 |
| US6309892B1 (en) | 2001-10-30 |
| EP0733214B1 (de) | 1998-05-06 |
| ES2118545T3 (es) | 1998-09-16 |
| US20020028473A1 (en) | 2002-03-07 |
| CA2175451A1 (en) | 1995-06-22 |
| US5525339A (en) | 1996-06-11 |
| DE69410116D1 (de) | 1998-06-10 |
| AU1269595A (en) | 1995-07-03 |
| WO1995016917A1 (en) | 1995-06-22 |
| DE69410116T2 (de) | 1998-12-17 |
| JPH09507748A (ja) | 1997-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE165918T1 (de) | Aus bestandteilen im gehirngewebe der säugetiere ableitbare dichte mikrokugeln und dagegen gerichtete antikörper | |
| AU4239196A (en) | Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease | |
| Zucker | Treatment of gender identity disorders in children. | |
| US5443960B1 (en) | Method for the diagnosis of blood coagulation disorders | |
| HUP9902068A3 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
| CA2245661A1 (en) | Multiple sclerosis treatment | |
| EP1445317A3 (de) | Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Krebs | |
| NO20100264L (no) | Forhindring og behandling av amyloidogen sykdom | |
| CA2164291A1 (en) | Methods and pharmaceutical compositions useful for treating neurological disorders | |
| NO961478L (no) | Levobupivacaine anvendelig for kontroll av kronisk smerte | |
| WO2001013905A3 (en) | Methods for the treatment of mental and vascular disorders | |
| WO2002016581A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO1995024650A3 (en) | Methods of diagnosing and treating preeclampsia | |
| WO2002016602A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO1999048489A3 (en) | Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders | |
| FR2827518B1 (fr) | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie | |
| WO2001082892A3 (de) | Wirkstoffhaltige liposome | |
| Parker | The distracting effects of pain, headaches, and hyper-arousal upon employment after" minor head injury." | |
| DE69124380D1 (de) | Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten | |
| WO2002062205A3 (en) | Methods for diagnosing and treating heart disease | |
| ATE240352T1 (de) | Komplexverbindungen zur diagnose von gefässerkrankungen | |
| WO2001042205A3 (en) | Treatment of inflammatory bowel disease with vitamin d compounds | |
| WO2003028536A3 (en) | Methods for diagnosing and treating heart disease | |
| ATE164230T1 (de) | 4verfahren und zusammensetzungen zur vorbeugung, diagnose und behandlung seröser entzündungen und damit verbundener störungen | |
| Leibman | The prisoner's right to psychiatric and psychological treatment. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |